Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN ETHYLSUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRA DERM versus ERYTHROMYCIN ETHYLSUCCINATE.
ERYTHRA-DERM vs ERYTHROMYCIN ETHYLSUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. It also exhibits anti-inflammatory and immunomodulatory effects, reducing neutrophil chemotaxis and bacterial lipase production.
Erythromycin ethylsuccinate is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also have anti-inflammatory and immunomodulatory effects.
Apply a thin layer to the affected area(s) twice daily. For topical use only. Adult dose is 2% solution or ointment.
400-800 mg orally every 6 hours or 4 times daily; maximum 4 g/day. Intravenous form available but ethylester is oral only.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; prolonged to 5-6 hours in hepatic impairment.
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; extended to 5-6 hours in patients with severe hepatic impairment; not significantly altered by renal failure.
Primarily biliary fecal elimination (60-70%); renal excretion of unchanged drug <15%.
Primarily hepatic metabolism and biliary excretion (80-90% as unchanged drug and metabolites into bile); renal excretion accounts for 5-15% of unchanged drug; fecal elimination of unabsorbed drug.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic